Stockreport

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook [Yahoo! Finance]

Foghorn Therapeutics Inc.  (FHTX) 
PDF • FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by partner Lilly; preclinical data to be presented at AACR with IND planned for t [Read more]